<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221555</url>
  </required_header>
  <id_info>
    <org_study_id>AMC2001</org_study_id>
    <nct_id>NCT04221555</nct_id>
  </id_info>
  <brief_title>Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma</brief_title>
  <official_title>Neoadjuvant Durvalumab (MEDI4736) Plus Docetaxel, Oxaliplatin, S-1 (DOS) Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient (pMMR) Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery&#xD;
      and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR)&#xD;
      gastric or gastroesophageal junction (GEJ) adenocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Treatment for the main treatment group (pMMR tumor)&#xD;
&#xD;
             1. Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2&#xD;
                intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally&#xD;
                on D1-14, will be administered every three weeks for three cycles.&#xD;
&#xD;
             2. Surgery&#xD;
&#xD;
             3. Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28&#xD;
                plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12&#xD;
                months as an adjuvant treatment.&#xD;
&#xD;
        -  Treatment for the exploratory group (dMMR tumor)&#xD;
&#xD;
             1. Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be&#xD;
                administered every four weeks for three cycles.&#xD;
&#xD;
             2. Surgery&#xD;
&#xD;
             3. Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be&#xD;
                administered every 4 weeks for 12 months as an adjuvant treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete regression (pCR) rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Resectable Gastric or Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>the main treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pMMR tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the exploratory group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dMMR tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Oxaliplatin, S-1 and Durvalumab</intervention_name>
    <description>Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.&#xD;
Surgery&#xD;
Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.</description>
    <arm_group_label>the main treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab and Tremelimumab</intervention_name>
    <description>Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.&#xD;
Surgery&#xD;
Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment.</description>
    <arm_group_label>the exploratory group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed pathologically proven potentially resectable gastric or GEJ&#xD;
             adenocarcinoma&#xD;
&#xD;
          2. Clinical stages of T3-4N0 or T2-4N+ according to the American Joint Committee on&#xD;
             Cancer (AJCC) 8th edition by computed tomography (CT)&#xD;
&#xD;
          3. Microsatellite-instability (MSI) status determined by immunohistochemical (IHC)&#xD;
             staining&#xD;
&#xD;
          4. No peritoneal seeding identified by laparoscopy if suspected by CT&#xD;
&#xD;
          5. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol. Written informed consent and any locally required authorization obtained&#xD;
             from the patient/legal representative prior to performing any protocol-related&#xD;
             procedures, including screening evaluations&#xD;
&#xD;
          6. Age &gt; 18 years at time of study entry&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          8. Life expectancy of &gt; 12 months&#xD;
&#xD;
          9. Body weight &gt; 30kg&#xD;
&#xD;
         10. No existing neuropathy&#xD;
&#xD;
         11. Adequate normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Haemoglobin ≥9.0 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) 1.5 (or 1.0) x (&gt; 1500 per mm3)&#xD;
&#xD;
               -  Platelet count ≥100 (or 75) x 109/L (&gt;75,000 per mm3)&#xD;
&#xD;
               -  Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  AST (SGOT)/ALT (SGPT) ≤2.5 x institutional ULN&#xD;
&#xD;
               -  Measured creatinine clearance (CL) &gt; 40 mL/min or Calculated creatinine CL&gt;40&#xD;
                  mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour&#xD;
                  urine collection for determination of creatinine clearance:&#xD;
&#xD;
         12. Evidence of post-menopausal status or negative urinary or serum pregnancy test for&#xD;
             female pre-menopausal patients. Women will be considered post-menopausal if they have&#xD;
             been amenorrheic for 12 months without an alternative medical cause.&#xD;
&#xD;
         13. Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical study with an investigational product during the&#xD;
             last 2 weeks&#xD;
&#xD;
          2. Concurrent enrollment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study or during the follow-up period of an&#xD;
             interventional study&#xD;
&#xD;
          3. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer&#xD;
             treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g.,&#xD;
             hormone replacementtherapy) is acceptable&#xD;
&#xD;
          4. Major surgical procedure within 28 days prior to the first dose of durvalumab&#xD;
&#xD;
          5. Distant metastasis including M1 lymph node&#xD;
&#xD;
          6. Unable to take medication orally&#xD;
&#xD;
          7. Gastric outlet obstruction and/or severe gastrointestinal bleeding&#xD;
&#xD;
          8. Impaired bowel absorption, including any of the following:&#xD;
&#xD;
               -  Bowel obstruction&#xD;
&#xD;
               -  Chronic inflammatory bowel disease&#xD;
&#xD;
               -  History of extended bowel resection&#xD;
&#xD;
               -  Gastric dumping syndrome&#xD;
&#xD;
          9. History of allogenic organ transplantation&#xD;
&#xD;
         10. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               -  Patients with vitiligo or alopecia&#xD;
&#xD;
               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               -  Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               -  Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               -  Patients with celiac disease controlled by diet alone&#xD;
&#xD;
         11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring adverse events (AEs) or compromise the ability of the patient to&#xD;
             give written informed consent&#xD;
&#xD;
         12. History of another primary malignancy except for&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease ≥ 5&#xD;
                  years before the first dose of durvalumab and of low potential risk for&#xD;
                  recurrence&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               -  Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
         13. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms&#xD;
             calculated from 3 ECGs (within 15 minutes at 5 minutes apart)&#xD;
&#xD;
         14. History of active primary immunodeficiency&#xD;
&#xD;
         15. Active infection including tuberculosis (clinical evaluation that includes clinical&#xD;
             history, physical examination and radiographic findings, and TB testing in line with&#xD;
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),&#xD;
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients&#xD;
             with a past or resolved HBV infection (defined as the presence of hepatitis B core&#xD;
             antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for&#xD;
             hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative&#xD;
             for HCV RNA.&#xD;
&#xD;
         16. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra&#xD;
                  articular injection)&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                  prednisone or its equivalent&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication)&#xD;
&#xD;
         17. Receipt of live attenuated vaccine within 30 days prior to the first dose of&#xD;
             durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst&#xD;
             receiving durvalumab and up to 30 days after the last dose of durvalumab&#xD;
&#xD;
         18. Female patients who are pregnant or breastfeeding or male or female patients of&#xD;
             reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 90 days after the last dose of durvalumab&#xD;
&#xD;
         19. Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients&#xD;
&#xD;
         20. Prior randomisation or treatment in a previous durvalumab or tremelimumab clinical&#xD;
             study regardless of treatment arm assignment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YoonKoo Yoon, MD, PhD</last_name>
    <phone>+82-2-3010-2043</phone>
    <email>ykkang@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min-Hee Ryu, MD, PhD</last_name>
    <phone>+82-2-3010-5935</phone>
    <email>miniryu@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <phone>82-2-3010-3230</phone>
      <email>ykkang@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Min-Hee Ryu, MD, PhD</last_name>
      <phone>82-2-3010-5935</phone>
      <email>miniryu@amc.seoul.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

